<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>14(18)</volume><submitter>Jiang C</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Amplification of 11q13 (FGF3/4/19, CCND1) is frequently observed in head and neck squamous cell carcinoma (HNSCC). However, there is a lack of research investigating 11q13 amplification as a prognostic marker for patients with locally advanced (LA) HNSCC who undergo postoperative radiotherapy (PORT).&lt;h4>Materials and methods&lt;/h4>This retrospective study included consecutive patients of LA-HNSCC who underwent radical surgical resection and PORT. The 11q13 amplification was tested by next-generation Sequencing (NGS) or fluorescent in situ hybridization (FISH). Propensity score matching (PSM) was used to match the amplification and wild-type groups. Univariate and multivariate analyses were conducted using Kaplan-Meier and Cox regression. Recurrence patterns and phenotypes </pubmed_abstract><journal>Cancer medicine</journal><pagination>e71235</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12449658</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Prognosis and Failure Patterns of 11q13 Amplified Local Advanced Squamous Cell Carcinoma of the Head and Neck.</pubmed_title><pmcid>PMC12449658</pmcid><pubmed_authors>Ye L</pubmed_authors><pubmed_authors>Jiang W</pubmed_authors><pubmed_authors>Fu X</pubmed_authors><pubmed_authors>Jiang C</pubmed_authors><pubmed_authors>Li R</pubmed_authors><pubmed_authors>Zhang L</pubmed_authors><pubmed_authors>Zhu G</pubmed_authors><pubmed_authors>Wang Y</pubmed_authors><pubmed_authors>Dou S</pubmed_authors></additional><is_claimable>false</is_claimable><name>Prognosis and Failure Patterns of 11q13 Amplified Local Advanced Squamous Cell Carcinoma of the Head and Neck.</name><description>&lt;h4>Background&lt;/h4>Amplification of 11q13 (FGF3/4/19, CCND1) is frequently observed in head and neck squamous cell carcinoma (HNSCC). However, there is a lack of research investigating 11q13 amplification as a prognostic marker for patients with locally advanced (LA) HNSCC who undergo postoperative radiotherapy (PORT).&lt;h4>Materials and methods&lt;/h4>This retrospective study included consecutive patients of LA-HNSCC who underwent radical surgical resection and PORT. The 11q13 amplification was tested by next-generation Sequencing (NGS) or fluorescent in situ hybridization (FISH). Propensity score matching (PSM) was used to match the amplification and wild-type groups. Univariate and multivariate analyses were conducted using Kaplan-Meier and Cox regression. Recurrence patterns and phenotypes </description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Sep</publication><modification>2026-06-03T15:32:38.316Z</modification><creation>2026-06-01T03:06:16.491Z</creation></dates><accession>S-EPMC12449658</accession><cross_references><pubmed>40974176</pubmed><doi>10.1002/cam4.71235</doi></cross_references></HashMap>